---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-018800"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:23:15.527771+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech Q1 net loss $8.5M; Phase 3 VERSATILE-003 trial underway

## Summary
- Net loss of $8.5M ($0.21 per share) in Q1 2025 vs $10.6M ($0.30) in Q1 2024; R&D expenses fell to $5.8M.
- Cash and equivalents $40M as of March 31, 2025; includes $11M from Feb 2025 registered direct offering with warrants for up to $11M more.
- VERSATILE-003 Phase 3 trial initiated for Versamune HPV + pembrolizumab in HPV16-positive HNSCC; targets ~350 patients with 2:1 randomization.
- FDA cleared IND for Versamune MUC1 + PDS01ADC in metastatic colorectal cancer; NCI to lead Phase 1/2 under CRADA.
- Three Versamune HPV abstracts selected for presentation at 2025 ASCO Annual Meeting (May 30-June 3).

## SEC filing metadata
- accession: 0001140361-25-018800
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125018800/0001140361-25-018800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125018800/ef20048917_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-018800
- JSON: https://secwatch.observer/filing/0001140361-25-018800.json
- Plain text: https://secwatch.observer/filing/0001140361-25-018800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.